# A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants

> **NCT06193148** · PHASE1 · COMPLETED · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 32 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Jaktinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06193148
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-19
- **Primary completion:** 2024-06-18
- **Final completion:** 2024-06-18
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06193148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06193148, "A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06193148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*